What is sarcoidosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Sarcoidosis?

Sarcoidosis is a multisystem inflammatory disease of unknown cause characterized by the formation of noncaseating (non-necrotizing) granulomas that can affect virtually any organ, most commonly the lungs and thoracic lymph nodes in approximately 90% of cases 1.

Core Definition and Pathology

Sarcoidosis represents a heterogeneous granulomatous disorder that predominantly affects adults aged 20-60 years, with higher prevalence in African Americans and Scandinavians 2, 3. The hallmark pathological feature is the presence of compact, tightly formed collections of large "epithelioid" histiocytes and multinucleated giant cells arranged in discrete granulomas with minimal to no necrosis 1.

Key Pathological Characteristics

The granulomas in sarcoidosis exhibit specific features that distinguish them from other granulomatous diseases 1:

  • Perilymphatic distribution: Located around bronchovascular bundles, fibrous septa containing pulmonary veins, and near visceral pleura
  • Nonnecrotic morphology: Absence of extensive necrosis (though focal minimal ischemic necrosis may occur)
  • Sparse surrounding lymphocytic infiltrate: Unlike other inflammatory conditions with robust inflammatory infiltrates
  • Negative microorganism stains and cultures: Critical for excluding infectious causes

Clinical Spectrum

The clinical presentation ranges dramatically from completely asymptomatic disease discovered incidentally on imaging to progressive organ dysfunction and life-threatening complications 1, 2. Mortality is significantly elevated in certain populations, with African American women showing 2.4-times higher mortality compared to matched cohorts without sarcoidosis 1.

Organ Involvement Patterns

Intrathoracic manifestations (90% of patients) 3:

  • Bilateral hilar lymphadenopathy
  • Diffuse lung micronodules along lymphatic structures
  • Pulmonary fibrosis in advanced cases

Common extrapulmonary manifestations (25-50% prevalence) 3:

  • Skin lesions (including lupus pernio)
  • Uveitis and ocular involvement
  • Liver or splenic involvement
  • Peripheral and abdominal lymphadenopathy
  • Peripheral arthritis

Life-threatening manifestations (<10% but critical) 1, 3:

  • Cardiac involvement (arrhythmias, sudden cardiac death, congestive heart failure)
  • Neurological involvement
  • Hypercalcemia with renal dysfunction

Diagnostic Approach

The diagnosis of sarcoidosis is never fully secure and remains a diagnosis of exclusion 1. It requires three major criteria 1, 3:

  1. Compatible clinical and/or radiological presentation
  2. Histological evidence of non-necrotizing granulomatous inflammation (not always required for highly specific syndromes)
  3. Exclusion of alternative causes of granulomatous disease

Highly Specific Clinical Syndromes (No Biopsy Required)

Certain presentations are considered diagnostic without histological confirmation 1, 3:

  • Löfgren's syndrome: Bilateral hilar adenopathy with erythema nodosum and/or periarticular arthritis
  • Lupus pernio: Specific chronic skin lesion
  • Heerfordt's syndrome: Parotid enlargement, uveitis, facial nerve palsy, and fever

Critical Differential Diagnoses

The differential diagnosis is extensive and must be systematically excluded 1:

  • Infections: Tuberculosis (38% of alternative diagnoses in suspected cases), fungal infections
  • Malignancies: Lymphoma (25% of alternative diagnoses), metastatic disease
  • Drug-induced granulomatosis: Immune checkpoint inhibitors and other immune-modulating drugs
  • Vasculitides: Granulomatosis with polyangiitis (differentiated by ANCA antibodies)
  • IgG4-related disease: Differentiated by elevated serum IgG4 levels and histopathology
  • Common variable immune deficiency: Can mimic multiorgan sarcoidosis

Disease Course and Prognosis

The natural history is highly variable 4, 5:

  • Many patients experience spontaneous resolution, particularly those with isolated bilateral hilar lymphadenopathy 1
  • Up to one-third develop chronic or progressive disease with increased risk of organ failure or death 5
  • Pulmonary hypertension, reduced lung function, and pulmonary fibrosis are associated with increased mortality risk 4

Common Pitfalls

Asymptomatic bilateral hilar lymphadenopathy is almost always caused by sarcoidosis and often represents self-limited disease 1. However, clinicians must remain vigilant as 10% may have lymphoma and 7.7% other serious diagnoses in symptomatic presentations 1. The key distinction is the presence or absence of B symptoms (fevers, night sweats, weight loss).

The disease is often called the "great mimicker" due to its remarkable variability in clinical presentation 6, requiring careful multidisciplinary evaluation to avoid misdiagnosis.

References

Guideline

diagnosis and detection of sarcoidosis. an official american thoracic society clinical practice guideline.

American Journal of Respiratory and Critical Care Medicine, 2020

Research

Symptoms, Causes, and Treatment of Sarcoidosis.

Mayo Clinic proceedings, 2026

Guideline

ers clinical practice guidelines on treatment of sarcoidosis.

European Respiratory Journal, 2021

Research

[Sarcoidosis].

Radiologie (Heidelberg, Germany), 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.